Autophagy as a therapeutic target in pancreatic cancer - Centre de recherche des Cordeliers Accéder directement au contenu
Article Dans Une Revue British Journal of Cancer Année : 2021

Autophagy as a therapeutic target in pancreatic cancer

Résumé

Pancreatic ductal adenocarcinoma (PDAC) is characterised by early metastasis and resistance to anti-cancer therapy, leading to an overall poor prognosis. Despite continued research efforts, no targeted therapy has yet shown meaningful efficacy in PDAC; mutations in the oncogene KRAS and the tumour suppressor TP53, which are the most common genomic alterations in PDAC, have so far shown poor clinical actionability. Autophagy, a conserved process allowing cells to recycle altered or unused organelles and cellular components, has been shown to be upregulated in PDAC and is implicated in resistance to both cytotoxic chemotherapy and targeted therapy. Autophagy is thus regarded as a potential therapeutic target in PDAC and other cancers. Although the molecular mechanisms of autophagy activation in PDAC are only beginning to emerge, several groups have reported interesting results when combining inhibitors of the extracellular-signal-regulated kinase/mitogen-activated protein kinase pathway and inhibitors of autophagy in models of PDAC and other KRAS-driven cancers. In this article, we review the existing preclinical data regarding the role of autophagy in PDAC, as well as results of relevant clinical trials with agents that modulate autophagy in this cancer.
Fichier principal
Vignette du fichier
s41416-020-01039-5.pdf (1.36 Mo) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03200374 , version 1 (16-04-2021)

Identifiants

Citer

Max Piffoux, Erwan Eriau, Philippe A Cassier. Autophagy as a therapeutic target in pancreatic cancer. British Journal of Cancer, 2021, 124 (2), pp.333-344. ⟨10.1038/s41416-020-01039-5⟩. ⟨hal-03200374⟩
74 Consultations
44 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More